5 active not recruiting. 5 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Active not recruiting 5 |
| Phase 2 | 3 | Active not recruiting 3 |
Follow Gallbladder Neoplasms: new trials by email Literature Review of Gallbladder Neoplasms trials Research Report on Gallbladder Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) Rilvegostomig, Placebo, Capecitabine - Biliary Tract Cancer | Phase 3 | Active not recruiting | AstraZeneca | 760 | 2023-12-04 | 2026-10-16 |
| A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) CTX-009, Paclitaxel - Biliary Tract Cancer, Cholangiocarcinoma | Phase 2 / Phase 3 | Active not recruiting | Compass Therapeutics | 168 | 2023-01-09 | 2026-09-02 |
| Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer Cisplatin, Gemcitabine Hydrochloride, Lymphadenectomy - Stage II Gallbladder Cancer AJCC v8, Stage IIA Gallbladder Cancer AJCC v8 | Phase 2 / Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 186 | 2021-02-24 | 2026-10-19 |
| Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers Gemcitabine, Cisplatin, Chemoradiation - Gall Bladder Cancers | Phase 2 / Phase 3 | Active not recruiting | Tata Memorial Hospital | 124 | 2016-09-06 | 2025-03-13 |
| Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer Gemcitabine, Cisplatin, Capecitabine - Cholangiocarcinoma, Gall Bladder Carcinoma | Phase 3 | Active not recruiting | Universitätsklinikum Hamburg-Eppendorf | 789 | 2014-04-01 | 2025-03-30 |
Cholangiocarcinoma (3) · Biliary Tract Neoplasms (2) · Bile Duct Neoplasms (1) · Klatskin Tumor (1)
Biliary Tract Diseases (5) · Digestive System Diseases (5) · Digestive System Neoplasms (5) · Gallbladder Diseases (5) · Neoplasms (5) · Neoplasms by Site (5) · Adenocarcinoma (3) · Biliary Tract Neoplasms (3) · Carcinoma (3) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3) · Bile Duct Diseases (1)
Cisplatin (4) · Gemcitabine (4) · Capecitabine (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Chemoradiotherapy (1) · Laparoscopy (1) · Lymph Node Excision (1) · Magnetic Resonance Spectroscopy (1) · Paclitaxel (1) · Platinum (1) · Radiotherapy, Intensity-Modulated (1) · S 1 (combination) (1) · Tegafur (1)
AstraZeneca (1) · Compass Therapeutics (1) · ECOG-ACRIN Cancer Research Group (1) · Tata Memorial Hospital (1) · Universitätsklinikum Hamburg-Eppendorf (1)
United States (3) · Australia (2) · Denmark (2) · Germany (2) · India (2) · Italy (2) · United Kingdom (2) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · China (1) · France (1) · Hong Kong (1) · Japan (1)
Cynthia Sirard, MD (1) · Henning Wege (1) · Reena Engineer, MBBS MD (1) · Shishir K Maithel (1)
PMID 26228433, PMID 31253621, PMID 38861293
2023 (1), U10CA180820 (1)